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Recent data from in vitro, animal, and human studies have shed new light on the positive roles of copper in many aspects of AD.
Copper promotes the non-amyloidogenic processing of APP and thereby lowers the Aβ production in cell culture systems, and
it increases lifetime and decreases soluble amyloid production in APP transgenic mice. In a clinical trial with Alzheimer patients,
the decline of Aβ levels in CSF, which is a diagnostic marker, is diminished in the verum group (8mg copper/day), indicating a
beneﬁcial eﬀect of the copper treatment. These observations are in line with the beneﬁt of treatment with compounds aimed at
normalizing metal levels in the brain, such as PBT2. The data reviewed here demonstrate that there is an apparent disturbance in
metal homeostasis in AD. More research is urgently needed to understand how this disturbance can be addressed therapeutically.
1. Copper: EssentialandPotentiallyToxic
Copper is needed by every oxygen-requiring cell and can be
toxicinexcess.Itisanessentialmetalwithextremelycomplex
r o l e si nn u m e r o u sd i ﬀerent biological functions from acute
phase reactant to mitochondrial energy generation. Cu
levels are very tightly regulated on the level of duodenal
absorption as well as uptake into cells or excretion from cells.
Intracellularly, it is transported by specialized chaperone-
like proteins to protect the ion from reactions with reactive
oxygen species [1].
Plasma Cu levels do not correspond to an individual’s
Cu exposure or Cu status. Cu serum levels rise during acute
phase, they correlate positively with estrogen levels, and can
also rise during many chronic disease states. This is caused
by an increase in a Cu-containing plasma protein called
ceruloplasmin (Cp). Most of the plasma Cu is bound to Cp
(up to 95%), with the remaining portion of the Cu being
bound to albumin or histidine residues in other proteins [2].
Ap o s s i b l er o l eo fC ui nA Dh a sr e m a i n e dac o n t e n t i o u s
topic during the past 15 years, as has been the question
whether extracellular amyloid deposited in plaques is the
causative agent in AD. The scientiﬁc community was divided
as to whether Cu has a role at all, and—if yes—whether it is
friend or foe.
Intensive basic research has led to a paradigm shift in
both unveiling a beneﬁcial role for Cu in AD on the one
handanddeleteriousfunctionsoflowerintracellularamyloid
oligomers consisting of the 42 amino acid residue amyloid-β
peptide (Aβ42).
2. Copper and Alzheimer’s Disease: Molecular
andInVitroFindings
On a molecular level, interactions between Cu and proteins
involved in AD are observed, that is, the amyloid precursor
protein (APP), the beta-site APP-cleaving enzyme 1
(BACE1), and the Aβ p e p t i d e .A P Ph a sar o l ei nC u - e ﬄux
[3] and binds Cu(II) via its extracellular domain [4, 5],
where bound Cu(II) is reduced to Cu(I) [6, 7]. Additionally,
APP traﬃcking is directly inﬂuenced by Cu. Cu treatment of
neuronal cells revealed an increase of APP at the cell surface
by both promoting its exocytosis from the Golgi and by
reducing its rate of endocytosis [8, 9]. BACE1 is an aspartic
protease, cleaving APP in the ﬁrst step of Aβ generation.2 International Journal of Alzheimer’s Disease
BACE1 binds a single Cu(I) atom with high aﬃnity through
cysteine residues of its C-terminal domain and interacts
with the cytoplasmic Cu-chaperone CCS (the Cu chaperone
for Cu, Zn-superoxide dismutase (SOD1)) through domain
I[ 10]. Aβ, which is part of the ectodomain and the trans-
membrane segment of APP, was also shown to bind Cu, and
Cu was found enriched in plaque deposits which mainly
consist of Aβ [11–14] .T h u s ,A P P ,B A C E 1 ,a n dA β are met-
alloproteins which can bind Cu and were experimentally
shown to be involved in brain Cu homeostasis.
In 1994, the aggregation of synthetic Aβ peptides into
assemblies of oligomers and ﬁbrils upon binding of Cu(II)
was reported [15]. It was the time before the toxicity of lower
Aβ oligomers was discovered and insoluble plaque amyl-
o i dw a sf o u n di n e r t[ 16]. Over the years, the hypothesis of
oligomers as causative agents was conﬁrmed [17]. Recent re-
search has provided evidence that oligomers were shown to
induce hyperphosphorylation of tau at AD-relevant epitopes
in hippocampal neurons, and thereby provided a strong link
between the pathological hallmarks of Aβ and tau deposits
[18]. Oligomers isolated from the AD brain were found
to potently induce AD-type tau phosphorylation. Tau was
found to form Cu-complexes with one Cu(II) ion bound per
monomer with a dissociation constant in the micromolar
range Cu(II), having an inhibiting eﬀect on the in vitro ag-
gregation of tau [19, 20]. However, since tau occurs intracel-
lularly and Cu(II) is mainly found in the extracellular space,
thelikelihoodthatthisreﬂectsaphysiologicalfunctionislow.
FindingssuchthathumanAβdirectlyproduceshydrogen
peroxide (H2O2) by a mechanism that involves the reduction
of metal ions, Fe(III) or Cu(II), setting up conditions for
Fenton-type chemistry [21] or that Cu(II) and Zn(II) inhibit
Aβ ﬁbrillization [22, 23] were all generated by in vitro assays
andwereneversystematicallyaddressedbyinvivomodelsys-
tems.
3. Copper and Alzheimer’s Disease:
FindingsinAnimalModels
Maynard et al. have shown that overexpression of the car-
boxy-terminal fragment of APP which contains the Aβ se-
quence elicits signiﬁcantly reduced Cu levels in transgenic
mouse brains [24]. Importantly, animal model systems of
AD and studies with living cells revealed that APP is actively
involved in balancing Cu concentrations. In APP and APLP2
knockout mice, Cu levels were found increased in cerebral
cortex and liver [25], whereas overexpression of APP was
reported to result in signiﬁcantly reduced Cu levels in the
brain of three transgenic mouse lines [24, 26].
APP23 mice (expressing human APP751 with the Swed-
ish mutation) have amyloidogenic deposits after 6 months
and more than half of the population dies before the age of
18 months. Treatment with clioquinol, a hydrophobic low-
aﬃnity Cu, and zinc chelator had a signiﬁcant beneﬁt in this
AD mouse model by normalizing, which is elevating, brain
Cu and zinc levels. In the treated animals brain, Aβ dep-
osition was decreased, and the general health of the animals
was improved [27].
Al a t e rs t u d yi nt w od i ﬀerent strains of amyloid-bear-
ing transgenic mice conﬁrmed the cognitive beneﬁts of clio-
quinol treatment [28]. Treatment with clioquinol’s second-
generation analogue, PBT2, rapidly restored cognition dis-
turbances in AD transgenic mice and was associated with
decreased interstitial Aβ [29]. Further, the neurotrophic ef-
fectsofPBT2haverecentlybeendemonstratedtodependup-
on metal uptake [30].
Consistentwiththeaboveﬁndings,adietarytreatmentof
APP23 transgenic mice with Cu sulfate for a 3-month inter-
val extended the lifetime of the mice considerably and re-
stored SOD-1 activity back to normal [26]. In agreement
with the beneﬁt of Cu treatment, Cu supplementation res-
cued premature death observed with clioquinol treatment of
APP transgenic mice [31]. This is in contrast, however, to the
above ﬁndings of beneﬁts of clioquinol and PBT2 treatment.
Taken together, these observations indicate that restoring
brain Cu homeostasis can have a beneﬁcial eﬀect on disease
progression in mouse models for AD. Cu levels can be nor-
malized by dietary treatment with bioavailable Cu salts, or
by treatment with clioquinol, which normalizes Cu and zinc
brain levels through the formation of metal-ion complexes
which are transported across cellular membranes.
In contrast, another animal model, hypercholesterolemic
rabbits, showed amyloid-inducing eﬀects mediated by low
Cu concentrations in drinking water (0.12mgCu/L) [32–
34]. This eﬀect was observed when Cu sulfate was added to
distilled water, and not when tap water was used in combi-
nation with the high cholesterol feed [32]. Potable tap water
typically contains at least this amount of Cu (0.12mgCu/L),
present as Cu carbonate or Cu carbonate hydroxide. Also,
when interpreting the ﬁndings in the hypercholesterolemic
animals, it needs to be kept in mind that high cholesterol
levels itself show Aβ-elevating eﬀects [35].
4. Copper and Alzheimer’s Disease:
Human Trials
Based on the animal study [26], oral intake of Cu(II) in AD
patients was investigated in a clinical trial. The eﬃcacy of
oral Cu supplementation in the treatment of AD patients
was evaluated for 12 months in a prospective, randomized,
double-blind, placebo-controlled phase 2 clinical trial in
patientswithmildAD.Sixty-eightsubjectswererandomized.
Patients with mild AD received either Cu-(II)-orotate-dihy-
drate (verum group; 8 mg Cu daily) or placebo (placebo
group). CSF was collected at beginning and at the end of
the study after 12 months. The treatment was well tolerated.
The primary outcome measures in CSF were Aβ42, Tau, and
Phospho-Tau. Cu intake had no eﬀect on the progression of
Tau and Phospho-Tau levels in CSF [36].
While Aβ42 levels declined by 30% in the placebo group
(P = 0.001), they decreased only by 10% (P = 0.04) in
the verum group [36]. Since decreased CSF Aβ42 is a diag-
nostic marker for AD, this observation indicated that Cu
treatment had a positive eﬀect on a relevant AD biomarker.
There were, however, no signiﬁcant diﬀerences in primary
outcomemeasures(ADAssessmentScale,Cognitivesubscale
(ADAScog), Mini Mental Status Examination) between theInternational Journal of Alzheimer’s Disease 3
verum and the placebo group [37]. Finally, CSF Aβ42 levels
declined signiﬁcantly in both groups within 12 months sup-
porting the notion that CSF Aβ42 may be valid not only for
diagnostic but also for prognostic purposes in AD [36].
Plasma Cu levels declined only in the placebo group dur-
ing the 12-month period. However, the outcome of the ran-
domization was such that the placebo group had higher Cu
levels at the beginning of the study. Cu levels in the verum
group were unchanged, which seems to be paradoxical. One
may speculate that Cu treatment normalized Cu levels in
plasma in the verum group by enhanced uptake and trans-
port and improved tissue homeostasis.
Previously, we have reported that signiﬁcantly lower
levels of Cu in plasma were found in those AD patients, who
fulﬁlled the criteria of CSF diagnosis for AD [38]. In addi-
tion, we observed reduced Cu levels in plasma in patients
with higher ADAScog scores (making more mistakes in this
neuropsychological test) [39]. However, Cu treatment had
no beneﬁcial eﬀect on cognitive abilities in AD patients of
the present clinical phase II pilot study [37]. There was no
correlation between plasma or CSF Cu and cholesterol levels.
The Cu-clinical trial demonstrates that long-term oral
intake of 8mg Cu (Cu-(II)-orotate-dihydrate) can be ex-
cluded as a risk factor for AD, and—based on the CSF bio-
marker analysis—that Cu may potentially play a beneﬁcial
role in this disease.
This is consistent with ﬁndings from a pilot phase II clin-
ical trial, where the placebo group deteriorated faster than
the clioquinol-treated group suggesting a beneﬁcial eﬀect of
clioquinol treatment [40]. In line with these observations,
treatment of AD patients with PBT2 in a phase IIa, double-
blind, randomized, placebo-controlled trial, PBT2 induced
a signiﬁcant improvement in cognitive performance after 12
weeks without changing plasma Cu levels [41].
Although we found beneﬁcial eﬀects of Cu, there are
contradicting results showing that elevated free serum Cu
levels (non-ceruloplasmin bound Cu) might be a risk factor
for AD [42–47]. A high proportion of the ceruloplasmin
of these patients was enzymatically inactive [47], indicating
that it contained less-than-normal Cu. Ceruloplasmin is the
main Cu carrier in plasma and has many roles, such as
ferroxidase or acute phase reactant. However, ceruloplasmin
is not a prerequisite for Cu delivery to the periphery [48].
The studies by Squitti, Arnal, and Brewer evaluating levels
of non-ceruloplasmin Cu in AD patients do not indicate the
chemical nature of this Cu. It is, therefore, unclear whether
or not this Cu is readily bioavailable or not. In any case,
inactiveceruloplasminandpotentiallylessbioavailable“free”
Cu will directly inﬂuence (i.e., lower) intracellular Cu levels
and impair the functions of proteins using Cu as a cofactor.
“Free” Cu can have negative eﬀects in the brain as seen in
disease states like Wilsons disease. However, levels of Cu in
CSFwerenotupregulatedinADasrevealedinametaanalysis
[49]. Instead, the study of Kessler et al. revealed reduced
plasma Cu and ceruloplasmin levels in patients with a CSF
diagnosis of advanced AD which supports previous observa-
tions that a mild Cu deﬁciency might contribute to AD
progression [38].
Whether the observed increase in the non-ceruloplasmin
Cu portion is a cause or consequence of the AD pathogenesis
also remains to be clariﬁed. The conclusion that Cu intake or
exposure can be a risk factor for AD cannot be drawn and
a direct comparison between the work by Squitti et al and
Brewer et al with an intervention study (8mg Cu orotate per
day, or treatment with PBT2) is diﬃcult.
5. Strategies to Rescue Copper Deﬁciency:
Chelators,Ionophores, and CuNanocarriers
APP and APLP2 extracellular domains, but not the extracel-
lular domain of APLP1, decreased intracellular Cu levels in
yeast cells and thus possess Cu-eﬄux activities in this test
system [3]. The addition of clioquinol-Cu complexes to the
yeast culture medium drastically increased the intracellular
Cu concentration, but there was no signiﬁcant eﬀect on
zinc levels. This ﬁnding conﬁrmed that facilitated metal-ion
transport can act therapeutically by changing the distribu-
tion of Cu or facilitating Cu uptake rather than by decreasing
Cu levels.
The expression of a mutant APP deﬁcient for Cu binding
increased intracellular Cu levels several fold [3]. These data
not only uncovered a novel biological function for APP and
APLP2 in cellular Cu homeostasis but also provided a new
conceptual framework for the formerly diverging theories of
Cu supplementation and chelation in the treatment of AD
[27]. These results also strictly contradict a proposed metal
chelation as a potential therapy for AD that was based on the
Aβ interaction with transition metals [50].
Findings described above [3] and in the section of ﬁnd-
ings from animal models [31] encouraged us to address Cu-
deﬁciency in AD by an aimed facilitation of Cu import into
the brain of Cu deﬁcient AD patients. Thus, several param-
etershavetobetakenintoconsideration,andseveralrequire-
m e n t sm u s tb er e g a r d e d .T h et r a n s p o r ta n dc e l l u l a rm e t a -
bolism of Cu depends on a series of membrane proteins
and smaller soluble proteins that comprise a functionally
integrated system for maintaining cellular Cu homeostasis.
BypassingthecellularCuuptakesystemwouldbeamean
to achieve higher local concentrations compared to normal
cellular uptake. We were able to show that synthetic sub-
stances called nanocarriers fulﬁll these requirements. They
speciﬁcally transport Cu to intracellular regions and enrich
local Cu concentrations (e.g. in endosomes versus cytosol)
[51]. Cu released from the carrier was bioavailable and com-
pensated decreased Cu levels in living cells. We and others
showed earlier that high intracellular Cu levels stimulate
the non-amyloidogenic pathway of APP processing, thereby,
diminishing levels of toxic Aβ peptides [52, 53]. Vice versa,
underconditionsoflowintracellularCu,APPproteolysiswas
shifted from non-amyloidogenic to amyloidogenic process-
ing [52, 54].
Taken together, Cu has beneﬁcial roles in the course of
AD based on the following observations: (i) it promotes the
non-amyloidogenic processing of APP and thereby lowers
the Aβ production in cell culture systems, (ii) it increases
lifetime and decreases soluble amyloid production in APP
transgenic mice, and (iii) in a clinical trial with AD patients,4 International Journal of Alzheimer’s Disease
the decline of Aβ levels in CSF, which is a diagnostic mark-
er, is diminished. More research is urgently required to un-
derstand why there is an apparent disturbance in metal




APP: Amyloid precursor protein
BACE1: Beta-site APP cleaving enzyme 1
Cp: Ceruloplasmin
Cu: Copper
PBT2: Second-generation 8-hydroxy quinoline analog
SOD1: Cu, Zn superoxide dismutase
ADAScog: AD Assessment Scale, Cognitive subscale.
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